Chapter 4 Emerging Roles of the Ubiquitin Proteasome System in Nuclear Hormone Receptor Signaling

Progress in Molecular Biology and Translational Science

Volumn 87, Issue C, 2009, Pages 117-135

  Lonard, David M ^a   O'Malley, Bert W ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL RECEPTOR; PROTEASOME; UBIQUITIN;

ANIMAL; HUMAN; METABOLISM; PROTEIN BINDING; PROTEIN PROCESSING; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; HUMANS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN BINDING; PROTEIN PROCESSING, POST-TRANSLATIONAL; RECEPTORS, CYTOPLASMIC AND NUCLEAR; SIGNAL TRANSDUCTION; UBIQUITIN;

EID: 77957056593     PISSN: 18771173     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1877-1173(09)87004-X     Document Type: Review

References (120)

1. Lonard D.M., and O'Malley B.W. Nuclear receptor coregulators: judges, juries, and executioners of cellular regulation. Mol Cell 27 (2007) 691-700
2. Lonard D.M., and O'Malley B.W. The expanding cosmos of nuclear receptor coactivators. Cell 125 (2006) 411 4
3. Lonard D.M., Lanz R.B., and O'Malley B.W. Nuclear receptor coregulators and human disease. Endocr Rev 28 (2007) 575 87
4. Tsai M.J., and O'Malley B.W. Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annu Rev Biochem 63 (1994) 451 86
5. Rosenfeld M.G., Lunyak V.V., and Glass C.K. Sensors and signals: a coactivator/corepressor/epigenetic code for integrating signal-dependent programs of transcriptional response. Genes Dev 20 (2006) 1405 28
6. Lee J.W., Ryan F., Swaffield J.C., Johnston S.A., and Moore D.D. Interaction of thyroid-hormone receptor with a conserved transcriptional mediator. Nature 374 (1995) 91 4
7. vom Baur E., Zechel C., Heery D., Heine M.J., Garnier J.M., Vivat V., et al. Differential ligand-dependent interactions between the AF-2 activating domain of nuclear receptors and the putative transcriptional intermediary factors mSUG1 and TIF1. EMBO J 15 (1996) 110 24
8. Glickman M.H., and Ciechanover A. The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol Rev 82 (2002) 373-428
9. Ravid T., and Hochstrasser M. Diversity of degradation signals in the ubiquitin-proteasome system. Nat Rev Mol Cell Biol 9 (2008) 679 90
10. Konstantinova I.M., Tsimokha A.S., and Mittenberg A.G. Role of proteasomes in cellular regulation. Int Rev Cell Mol Biol 267 (2008) 59-124
11. Heinemeyer W., Ramos P.C., and Dohmen R.J. The ultimate nanoscale mincer: assembly, structure and active sites of the 20S proteasome core. Cell Mol Life Sci 61 (2004) 1562 78
12. Weake V.M., and Workman J.L. Histone ubiquitination: triggering gene activity. Mol Cell 29 (2008) 653 63
13. Hill C.P., Masters E.I., and Whitby F.G. The 11S regulators of 20S proteasome activity. Curr Top Microbiol Immunol 268 (2002) 73-89
14. Swaffield J.C., Bromberg J.F., and Johnston S.A. Alterations in a yeast protein resembling HIV Tat-binding protein relieve requirement for an acidic activation domain in GAL4. Nature 357 (1992) 698-700
15. Swaffield J.C., Melcher K., and Johnston S.A. A highly conserved ATPase protein as a mediator between acidic activation domains and the TATA-binding protein. Nature 374 (1995) 88-91
16. Briggs S.D., Xiao T., Sun Z.W., Caldwell J.A., Shabanowitz J., Hunt D.F., et al. Gene silencing: trans-histone regulatory pathway in chromatin. Nature 418 (2002) 498
17. Lee D., Ezhkova E., Li B., Pattenden S.G., Tansey W.P., and Workman J.L. The proteasome regulatory particle alters the SAGA coactivator to enhance its interactions with transcriptional activators. Cell 123 (2005) 423 36
18. Pham A.D., and Sauer F. Ubiquitin-activating/conjugating activity of TAFII250, a mediator of activation of gene expression in Drosophila. Science 289 (2000) 2357 60
19. Geng F., and Tansey W.P. Polyubiquitylation of histone H2B. Mol Biol Cell 19 (2008) 3616 24
20. Branzei D., and Foiani M. Regulation of DNA repair throughout the cell cycle. Nat Rev Mol Cell Bio 9 (2008) 297-308
21. Dhananjayan S.C., Ismail A., and Nawaz Z. Ubiquitin and control of transcription. Essays Biochem 41 (2005) 69-80
22. Mittenberg A.G., Moiseeva T.N., and Barlev N.A. Role of proteasomes in transcription and their regulation by covalent modifications. Front Biosci 13 (2008) 7184 92
23. Jensen E.V., Suzuki T., Numata M., Smith S., and DeSombre E.R. Estrogen-binding substances of target tissues. Steroids 13 (1969) 417 27
24. Horwitz K.B., and McGuire W.L. Actinomycin D prevents nuclear processing of estrogen receptor. J Biol Chem 253 (1978) 6913 22
25. Mockus M.B., and Horwitz K.B. Progesterone receptors in human breast cancer. Stoichiometric translocation and nuclear receptor processing. J Biol Chem 258 (1983) 4778 83
26. Nawaz Z., Lonard D.M., Dennis A.P., Smith C.L., and O'Malley B.W. Proteasome-dependent degradation of the human estrogen receptor. Proc Natl Acad Sci USA 96 (1999) 1858 62
27. Lonard D.M., Nawaz Z., Smith C.L., and O'Malley B.W. The 26S proteasome is required for estrogen receptor-alpha and coactivator turnover and for efficient estrogen receptor-α transactivation. Mol Cell 5 (2000) 939 48
28. Dace A., Zhao L., Park K.S., Furuno T., Takamura N., Nakanishi M., et al. Hormone binding induces rapid proteasome-mediated degradation of thyroid hormone receptors. Proc Natl Acad Sci USA 97 (2000) 8985 90
29. Yoshida H., Kitamura K., Tanaka K., Omura S., Miyazaki T., Hachiya T., et al. Accelerated degradation of PML-retinoic acid receptor α (PML-RARα) oncoprotein by all-trans-retinoic acid in acute promyelocytic leukemia: possible role of the proteasome pathway. Cancer Res 56 (1996) 2945 8
30. Zhu J., Gianni M., Kopf E., Honoré N., Chelbi-Alix M., Koken M., et al. Retinoic acid induces proteasome-dependent degradation of retinoic acid receptor α (RARα) and oncogenic RARα fusion proteins. Proc Natl Acad Sci USA 96 (1999) 14807 12
31. Kopf E., Plassat J.L., Vivat V., de Thé H., Chambon P., and Rochette-Egly C. Dimerization with retinoid X receptors and phosphorylation modulate the retinoic acid-induced degradation of retinoic acid receptors α and γ through the ubiquitin-proteasome pathway. J Biol Chem 275 (2000) 33280 8
32. Wallace A.D., and Cidlowski J.A. Proteasome-mediated glucocorticoid receptor degradation restricts transcriptional signaling by glucocorticoids. J Biol Chem 276 (2001) 42714 21
33. Schaaf M.J., and Cidlowski J.A. Molecular determinants of glucocorticoid receptor mobility in living cells: the importance of ligand affinity. Mol Cell Biol 23 (2003) 1922 34
34. Yokota K., Shibata H., Kobayashi S., Suda N., Murai A., Kurihara I., et al. Proteasome-mediated mineralocorticoid receptor degradation attenuates transcriptional response to aldosterone. Endocr Res 30 (2004) 611 6
35. Tirard M., Almeida O.F., Hutzler P., Melchior F., and Michaelidis T.M. Sumoylation and proteasomal activity determine the transactivation properties of the mineralocorticoid receptor. Mol Cell Endocrinol 268 (2007) 20 9
36. Wiese R.J., Uhland-Smith A., Ross T.K., Prahl J.M., and DeLuca H.F. Up-regulation of the vitamin D receptor in response to 1,25-dihydroxyvitamin D3 results from ligandinduced stabilization. J Biol Chem 267 (1992) 20082 6
37. Masuyama H., and MacDonald P.N. Proteasome-mediated degradation of the vitamin D receptor (VDR) and a putative role for SUG1 interaction with the AF-2 domain of VDR. J Cell Biochem 71 (1998) 429 40
38. Kemppainen J.A., Lane M.V., Sar M., and Wilson E.M. Androgen receptor phosphorylation, turnover, nuclear transport, transcriptional activation. Specificity for steroids and antihormones. J Biol Chem 267 (1992) 968 74
39. Zhou Z., Lane M.V., Kemppainen J.A., French F.S., and Wilson E.M. Specificity of ligand-dependent androgen receptor stabilization: receptor domain interactions influence ligand dissociation and receptor stability. Mol Endocrinol 9 (1995) 208 18
40. Reid G., Hübner M.R., Métivier R., Brand H., Denger S., Manu D., et al. Cyclic, proteasome-mediated turnover of unliganded and liganded ERα on responsive promoters is an integral feature of estrogen signaling. Mol Cell 11 (2003) 695-707
41. Kiang D.T., Killander R.E., Thomas T., and Kennedy B.J. Up-regulation of estrogen receptors by nonsteroidal antiestrogens in human breast cancer. Cancer Res 49 (1989) 5312 6
42. Wittmann B.M., Sherk A., and McDonnell D.P. Definition of functionally important mechanistic differences among selective estrogen receptor down-regulators. Cancer Res 67 (2007) 9549 60
43. Dauvois S., Danielian P.S., White R., and Parker M.G. Antiestrogen ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover. Proc Natl Acad Sci USA 89 (1992) 4037 41
44. Wijayaratne A.L., Nagel S.C., Paige L.A., Christensen D.J., Norris J.D., Fowlkes D.M., and McDonnell D.P. Comparative analyses of mechanistic differences among antiestrogens. Endocrinology 140 (1999) 5828 40
45. Fan M., Nakshatri H., and Nephew K.P. Inhibiting proteasomal proteolysis sustains estrogen receptor-alpha activation. Mol Endocrinol 18 (2004) 2603 15
46. Tsai H.W., Katzenellenbogen J.A., Katzenellenbogen B.S., and Shupnik M.A. Protein kinase A activation of estrogen receptor α transcription does not require proteasome activity and protects the receptor from ligand-mediated degradation. Endocrinology 145 (2004) 2730 8
47. Kinyamu H.K., Collins J.B., Grissom S.F., Hebbar P.B., and Archer T.K. Genome wide transcriptional profiling in breast cancer cells reveals distinct changes in hormone receptor target genes and chromatin modifying enzymes after proteasome inhibition. Mol Carcinog 47 (2008) 845 85
48. Dennis A.P., Lonard D.M., Nawaz Z., and O'Malley B.W. Inhibition of the 26S proteasome blocks progesterone receptor-dependent transcription through failed recruitment of RNA polymerase II. J Steroid Biochem Mol Biol 94 (2005) 337 46
49. Sheflin L., Keegan B., Zhang W., and Spaulding S.W. Inhibiting proteasomes in human HepG2 and LNCaP cells increases endogenous androgen receptor levels. Biochem Biophys Res Commun 276 (2000) 144 50
50. Lin H.K., Altuwaijri S., Lin W.J., Kan P.Y., Collins L.L., and Chang C. Proteasome activity is required for androgen receptor transcriptional activity via regulation of androgen receptor nuclear translocation and interaction with coregulators in prostate cancer cells. J Biol Chem 277 (2002) 36570 6
51. Poole A.J., Li Y., Kim Y., Lin S.C., Lee W.H., and Lee E.Y. Prevention of Brca1-mediated mammary tumorigenesis in mice by a progesterone antagonist. Science 314 (2006) 1467 70
52. Chen P.H., Tsao Y.P., Wang C.C., and Chen S.L. Nuclear receptor interaction protein, a coactivator of androgen receptors (AR), is regulated by AR and Sp1 to feed forward and activate its own gene expression through AR protein stability. Nucleic Acids Res 36 (2008) 51-66
53. Kang Z., Pirskanen A., Jänne O.A., and Palvimo J.J. Involvement of proteasome in the dynamic assembly of the androgen receptor transcription complex. J Biol Chem 277 (2002) 48366 71
54. Stenoien D.L., Cummings C.J., Adams H.P., Mancini M.G., Patel K., DeMartino G.N., et al. Polyglutamine-expanded androgen receptors form aggregates that sequester heat shock proteins, proteasome components and SRC-1, and are suppressed by the HDJ-2 chaperone. Hum Mol Genet 8 (1999) 731 41
55. Lin H.K., Altuwaijri S., Lin W.J., Kan P.Y., Collins L.L., and Chang C. Proteasome activity is required for androgen receptor transcriptional activity via regulation of androgen receptor nuclear translocation and interaction with coregulators in prostate cancer cells. J Biol Chem 277 (2002) 36570 6
56. Palazzolo I., Gliozzi A., Rusmini P., Sau D., Crippa V., Simonini F., et al. The role of the polyglutamine tract in androgen receptor. J Steroid Biochem Mol Biol 108 (2008) 245 53
57. Chandra S., Shao J., Li J.X., Li M., Longo F.M., and Diamond M.I. A common motif targets huntingtin and the androgen receptor to the proteasome. J Biol Chem 283 (2008) 23950 5
58. Palazzolo I., Gliozzi A., Rusmini P., Sau D., Crippa V., Simonini F., et al. The role of the polyglutamine tract in androgen receptor. J Steroid Biochem Mol Biol 108 (2008) 245 53
59. Chandra S., Shao J., Li J.X., Li M., Longo F.M., and Diamond M.I. A common motif targets huntingtin and the androgen receptor to the proteasome. J Biol Chem 283 (2008) 23950 5
60. Fan M., Park A., and Nephew K.P. CHIP (carboxyl terminus of Hsc70-interacting protein) promotes basal and geldanamycin-induced degradation of estrogen receptor-α. Mol Endocrinol 19 (2005) 2901 14
61. Tateishi Y., Kawabe Y., Chiba T., Murata S., Ichikawa K., Murayama A., et al. Ligand-dependent switching of ubquitin-proteasome pathways for estrogen receptor. EMBO J 23 (2004) 4813 23
62. Horie K., Urano T., Ikeda K., and Inoue S. Estrogen-responsive RING finger protein controls breast cancer growth. J Steroid Biochem Mol Biol 85 (2003) 101 4
63. Park S., Song J., Joe C.O., and Shin I. Akt stabilizes estrogen receptor alpha with the concomitant reduction in its transcriptional activity. Cell Signal 20 (2008) 1368 74
64. Lange C.A., Shen T., and Horwitz K.B. Phosphorylation of human progesterone receptors at serine-294 by mitogen-activated protein kinase signals their degradation by the 26S proteasome. Proc Natl Acad Sci USA 97 (2000) 1032 7
65. Chauchereau A., Amazit L., Quesne M., Guiochon-Mantel A., and Milgrom E. Sumoylation of the progesterone receptor and of the steroid receptor coactivator SRC-1. J Biol Chem 278 (2003) 12335 43
66. Daniel A.R., Faivre E.J., and Lange C.A. Phosphorylation-dependent antagonism of sumoylation derepresses progesterone receptor action in breast cancer cells. Mol Endocrinol 21 (2007) 2890 906
67. Zhang P.J., Zhao J., Li H.Y., Man J.H., He K., Zhou T., et al. CUE domain containing 2 regulates degradation of progesterone receptor by ubiquitin-proteasome. EMBO J 26 (2007) 1831 42
68. Su K., Yang X., Roos M.D., Paterson A.J., and Kudlow J.E. Human Sug1/p45 is involved in the proteasome-dependent degradation of Sp1. Biochem J 348 (2000) 281 9
69. Masuyama H., and Hiramatsu Y. Involvement of suppressor for Gal 1 in the ubiquitin/proteasome-mediated degradation of estrogen receptors. J Biol Chem 279 (2004) 12020 6
70. Ghislain M., Udvardy A., and Mann C. S. cerevisiae 26S protease mutants arrest cell division in G2/metaphase. Nature 366 (1993) 358 62
71. Wójcik C., and DeMartino G.N. Intracellular localization of proteasomes. Int J Biochem Cell Biol 35 (2003) 579 89
72. Nawaz Z., Lonard D.M., Smith C.L., Lev-Lehman E., Tsai S.Y., Tsai M.J., and O'Malley B.W. The Angelman syndrome-associated protein, E6-AP, is a coactivator for the nuclear hormone receptor superfamily. Mol Cell Biol 19 (1999) 1182 9
73. Jiang Y.H., and Beaudet A.L. Human disorders of ubiquitination and proteasomal degradation. Curr Opin Pediatr 16 (2004) 419 26
74. Matentzoglu K., and Scheffner M. Ubiquitin ligase E6-AP and its role in human disease. Biochem Soc Trans 36 (2008) 797-801
75. Picard N., Charbonneau C., Sanchez M., Licznar A., Busson M., Lazennec G., et al. Phosphorylation of activation function-1 regulates proteasome-dependent nuclear mobility and E6-associated protein ubiquitin ligase recruitment to the estrogen receptor β. Mol Endocrinol 22 (2008) 317 30
76. Imhof M.O., and McDonnell D.P. Yeast RSP5 and its human homolog hRPF1 potentiate hormone-dependent activation of transcription by human progesterone and glucocorticoid receptors. Mol Cell Biol 16 (1996) 2594 605
77. Huibregtse J.M., Yang J.C., and Beaudenon S.L. The large subunit of RNA polymerase II is a substrate of the Rsp5 ubiquitin-protein ligase. Proc Natl Acad Sci USA 94 (1997) 3656 61
78. Yan J., Kim Y.S., Yang X.P., Albers M., Koegl M., and Jetten A.M. Ubiquitin-interaction motifs of RAP80 are critical in its regulation of estrogen receptor α. Nucleic Acids Res 35 (2007) 1673 86
79. Grossman S.R., Deato M.E., Brignone C., Chan H.M., Kung A.L., Tagami H., et al. Polyubiquitination of p53 by a ubiquitin ligase activity of p300. Science 300 (2003) 342 4
80. Hoppe T. Multiubiquitylation by E4 enzymes: "one size" doesn't fit all. Trends Biochem Sci 30 (2005) 183 7
81. Nijman S.M., Luna-Vargas M.P., Velds A., Brummelkamp T.R., Dirac A.M., Sixma T.K., et al. A genomic and functional inventory of deubiquitinating enzymes. Cell 123 (2005) 773 86
82. Faus H., Meyer H.A., Huber M., Bahr I., and Haendler B. The ubiquitin-specific protease USP10 modulates androgen receptor function. Mol Cell Endocrinol 245 (2005) 138 46
83. Zhao Y., Lang G., Ito S., Bonnet J., Metzger E., Sawatsubashi S., et al. A TFTC/STAGA module mediates histone H2A and H2B deubiquitination, coactivates nuclear receptors, and counteracts heterochromatin silencing. Mol Cell 29 (2008) 92-101
84. Zhu P., Zhou W., Wang J., Puc J., Ohgi K.A., Erdjument-Bromage H., et al. A histone H2A deubiquitinase complex coordinating histone acetylation and H1 dissociation in transcriptional regulation. Mol Cell 27 (2007) 609 21
85. Zhang J., Guenther M.G., Carthew R.W., and Lazar M.A. Proteasomal regulation of nuclear receptor corepressor-mediated repression. Genes Dev 12 (1998) 1775 80
86. Perissi V., Aggarwal A., Glass C.K., Rose D.W., and Rosenfeld M.G. A corepressor/coactivator exchange complex required for transcriptional activation by nuclear receptors and other regulated transcription factors. Cell 116 (2004) 511 26
87. Perissi V., Scafoglio C., Zhang J., Ohgi K.A., Rose D.W., Glass C.K., et al. TBL1 and TBLR1 phosphorylation on regulated gene promoters overcomes dual CtBP and NCoR/SMRT transcriptional repression checkpoints. Mol Cell 29 (2008) 755 66
88. Li X., Lonard D.M., Jung S.Y., Malovannaya A., Feng Q., Qin J., et al. The SRC-3/AIB1 coactivator is degraded in a ubiquitin- and ATP-independent manner by the REGγ proteasome. Cell 124 (2006) 381 92
89. Wu R.C., Feng Q., Lonard D.M., and O'Malley B.W. SRC-3 coactivator functional lifetime is regulated by a phospho-dependent ubiquitin time clock. Cell 129 (2007) 1125 40
90. Mori Y., Moriishi K., and Matsuura Y. Hepatitis C virus core protein: its coordinate roles with PA28gamma in metabolic abnormality and carcinogenicity in the liver. Int J Biochem Cell Biol 40 (2008) 1437 42
91. Li X., Amazit L., Long W., Lonard D.M., Monaco J.J., and O'Malley B.W. Ubiquitin- and ATP-independent proteolytic turnover of p21 by the REGγ-proteasome pathway. Mol Cell 26 (2007) 831 42
92. Wu R.C., Qin J., Yi P., Wong J., Tsai S.Y., Tsai M.J., et al. Selective phosphorylations of the SRC-3/AIB1 coactivator integrate genomic reponses to multiple cellular signaling pathways. Mol Cell 15 (2004) 937 49
93. Ferrero M., Avivar A., García-Macías M.C., and de Mora J.F. Phosphoinositide 3-kinase/AKT signaling can promote AIB1 stability independently of GSK3 phosphorylation. Cancer Res 68 (2008) 5450 9
94. Lonard D.M., and O'Malley B.W. SRC-3 transcription-coupled activation, degradation, and the ubiquitin clock: is there enough coactivator to go around in cells. Sci Signal 1 (2008) pe16
95. Yi P., Feng Q., Amazit L., Lonard D.M., Tsai S.Y., Tsai M.J., et al. Atypical protein kinase C regulates dual pathways for degradation of the oncogenic coactivator SRC-3/AIB1. Mol Cell 29 (2008) 465 76
96. Li C., Liang Y.Y., Feng X.H., Tsai S.Y., Tsai M.J., and O'Malley B.W. Essential phosphatases and a phospho-degron are critical for regulation of SRC-3/AIB1 coactivator function and turnover. Mol Cell 31 (2008) 835 49
97. Yi P., Wu R.C., Sandquist J., Wong J., Tsai S.Y., Tsai M.J., et al. Peptidyl-prolyl isomerase 1 (Pin1) serves as a coactivator of steroid receptor by regulating the activity of phosphorylated steroid receptor coactivator 3(SRC-3/AIB1). Mol Cell Biol 25 (2005) 9687 99
98. Mani A., Oh A.S., Bowden E.T., Lahusen T., Lorick K.L., Weissman A.M., et al. E6AP mediates regulated proteasomal degradation of the nuclear receptor coactivator amplified in breast cancer 1 in immortalized cells. Cancer Res 66 (2006) 8680 6
99. Li C., Wu R.C., Amazit L., Tsai S.Y., Tsai M.J., and O'Malley B.W. Specific amino acid residues in the basic helix-loop-helix domain of SRC-3 are essential for its nuclear localization and proteasome-dependent turnover. Mol Cell Biol 27 (2007) 1296 308
100. Baumann C.T., Ma H., Wolford R., Reyes J.C., Maruvada P., Lim C., et al. The glucocorticoid receptor interacting protein 1 (GRIP1) localizes in discrete nuclear foci that associate with ND10 bodies and are enriched in components of the 26S proteasome. Mol Endocrinol 15 (2001) 485-500
101. Fenne I.S., Hoang T., Hauglid M., Sagen J.V., Lien E.A., and Mellgren G. Recruitment of coactivator glucocorticoid receptor interacting protein 1 to an estrogen receptor transcription complex is regulated by the 3′,5′-cyclic adenosine 5′-monophosphate-dependent protein kinase. Endocrinology 149 (2008) 4336 45
102. Hoang T., Fenne S., Cook C., Børud B., Bakke M., Lien E.A., et al. cAMP-dependent protein kinase regulates ubiquitin-proteasome-mediated degradation and subcellular localization of the nuclear receptor coactivator GRIP1. J Biol Chem 279 (2004) 49120 30
103. Linares L.K., Kiernan R., Triboulet R., Chable-Bessia C., Latreille D., Cuvier O., et al. Intrinsic ubiquitination activity of PCAF controls the stability of the oncoprotein Hdm2. Nat Cell Biol 9 (2007) 331 8
104. Brooks C.L., and Gu W. Ubiquitination, phosphorylation and acetylation: the molecular basis for p53 regulation. Curr Opin Cell Biol 15 (2003) 164 71
105. Olson B.L., Hock M.B., Ekholm-Reed S., Wohlschlegel J.A., Dev K.K., Kralli A., et al. SCFCdc4 acts antagonistically to the PGC-1α transcriptional coactivator by targeting it for ubiquitin-mediated proteolysis. Genes Dev 22 (2008) 252 64
106. 2+ induce PGC-1α degradation through calpain. Arch Biochem Biophys 478 (2008) 130 5
107. Kerscher O., Felberbaum R., and Hochstrasser M. Modification of proteins by ubiquitin and ubiquitin-like proteins. Annu Rev Cell Dev Biol 22 (2006) 159 80
108. Poukka H., Karvonen U., Janne O.A., and Palvimo J.J. Covalent modification of the androgen receptor by small ubiquitin-like modifier (SUMO-1). Proc Natl Acad Sci USA 97 (2000) 14145 50
109. Poukka H., Aarnisalo P., Karvonen U., Palvimo J.J., and Jänne O.A. Ubc9 interacts with the androgen receptor and activates receptor-dependent transcription. J Biol Chem 274 (1999) 19441 6
110. Anckar J., and Sistonen L. SUMO: getting it on. Biochem Soc Trans 35 (2007) 1409 13
111. Liu B., and Shuai K. Regulation of the sumoylation system in gene expression. Curr Opin Cell Biol 20 (2008) 288 93
112. Kotaja N., Karvonen U., Jänne O.A., and Palvimo J.J. The nuclear receptor interaction domain of GRIP1 is modulated by covalent attachment of SUMO-1. J Biol Chem 277 (2002) 30283 8
113. Bawa-Khalfe T., Cheng J., Wang Z., and Yeh E.T. Induction of the SUMO-specific protease 1 transcription by the androgen receptor in prostate cancer cells. J Biol Chem 282 (2007) 37341 9
114. Cheng J., Bawa T., Lee P., Gong L., and Yeh E.T. Role of desumoylation in the development of prostate cancer. Neoplasia 8 (2006) 667 76
115. Sentis S., Le Romancer M., Bianchin C., Rostan M.C., and Corbo L. Sumoylation of the estrogen receptor alpha hinge region regulates its transcriptional activity. Mol Endocrinol 19 (2005) 2671 84
116. Wu H., Sun L., Zhang Y., Chen Y., Shi B., Li R., et al. Coordinated regulation of AIB1 transcriptional activity by sumoylation and phosphorylation. J Biol Chem 281 (2006) 21848 56
117. Rytinki M.M., and Palvimo J.J. SUMOylation modulates the transcription repressor function of RIP140. J Biol Chem 283 (2008) 11586 95
118. Fan M., Long X., Bailey J.A., Reed C.A., Osborne E., Gize E.A., et al. The activating enzyme of NEDD8 inhibits steroid receptor function. Mol Endocrinol 16 (2002) 315 30
119. Fan M., Bigsby R.M., and Nephew K.P. The NEDD8 pathway is required for proteasome-mediated degradation of human estrogen receptor (ER)-α and essential for the antiproliferative activity of ICI 182,780 in ERα-positive breast cancer cells. Mol Endocrinol 17 (2003) 356 65
120. Parry G., and Estelle M. Regulation of cullin-based ubiquitin ligases by the Nedd8/RUB ubiquitin-like proteins. Semin Cell Dev Biol 15 (2004) 221 9